Home › Myeloproliferative Neoplasms
Myeloproliferative Neoplasms clinical trials recruiting in the U.S.
50 studies for Myeloproliferative Neoplasms are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX16 studies
- New York City, NY15 studies
- Boston, MA14 studies
- Milwaukee, WI10 studies
- Miami, FL10 studies
- Seattle, WA9 studies
- Durham, NC9 studies
- Baldwin Park, CA9 studies
- Chicago, IL9 studies
- Philadelphia, PA8 studies
- St. Louis, MO8 studies
- Cleveland, OH8 studies
- Portland, OR8 studies
- Tampa, FL8 studies
- Columbus, OH8 studies
- Salt Lake City, UT8 studies
- Birmingham, AL8 studies
- Winston-Salem, NC7 studies
- Mountain View, CA7 studies
- Baltimore, MD7 studies
- Kansas City, MO7 studies
- Atlanta, GA7 studies
- Los Angeles, CA6 studies
- Jacksonville, FL6 studies
- Irvine, CA6 studies
- Ann Arbor, MI6 studies
- Phoenix, AZ6 studies
- Charlotte, NC6 studies
- Nashville, TN5 studies
- Rochester, MN5 studies
- Edison, NJ5 studies
- San Francisco, CA5 studies
- Pittsburgh, PA5 studies
- Charlottesville, VA5 studies
- Washington, DC5 studies
- Omaha, NE5 studies
- Sacramento, CA5 studies
- Minneapolis, MN5 studies
- Aurora, CO4 studies
- Greenville, NC4 studies
By state
- Alabama8 studies
- Arizona8 studies
- Arkansas4 studies
- California16 studies
- Colorado6 studies
- Connecticut5 studies
- Florida13 studies
- Georgia9 studies
- Hawaii3 studies
- Idaho4 studies
- Illinois9 studies
- Indiana4 studies
- Iowa4 studies
- Kansas6 studies
- Kentucky3 studies
- Louisiana4 studies
- Maine4 studies
- Maryland8 studies
- Massachusetts15 studies
- Michigan8 studies
- Minnesota8 studies
- Mississippi4 studies
- Missouri8 studies
- Montana3 studies
- Nebraska5 studies
- Nevada3 studies
- New Jersey5 studies
- New Mexico4 studies
- New York15 studies
- North Carolina13 studies
- Ohio11 studies
- Oklahoma5 studies
- Oregon8 studies
- Pennsylvania10 studies
- Rhode Island4 studies
- South Carolina5 studies
- Tennessee7 studies
- Texas18 studies
- Utah8 studies
- Vermont3 studies
- Virginia6 studies
- Washington9 studies
- Wisconsin10 studies
Recently updated studies
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Sep 29, 2026 · NCT06303193A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06661915MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07469891Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT03630991Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03471260Cord Blood Transplant in Adults With Blood Cancers
RecruitingPhase 2
Ages 21 to 65 · All sexes · Updated Sep 11, 2026 · NCT05884333Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06291987Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06523556Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT04493164Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Recruiting
Ages 19 and older · All sexes · Updated Aug 19, 2026 · NCT04898790Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07565220A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT07249840A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07020533Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Jul 22, 2026 · NCT06013423Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694Evaluation of the Pathobiology of CALR-mutated MPN Cells
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT06480591Asciminib Roll-over Study
RecruitingPhase 4
Ages 7 to 100 · All sexes · Updated Jul 6, 2026 · NCT04877522Allo HSCT Using RIC and PTCy for Hematological Diseases
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.